Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
Jessica Wagoner, Shawn Herring, Tien-Ying Hsiang, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19
Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
Med (2024) Vol. 5, Iss. 1, pp. 42-61.e23
Open Access | Times Cited: 20
Preparing for the next viral threat with broad-spectrum antivirals
Marwah Karim, Chieh‐Wen Lo, Shirit Einav
Journal of Clinical Investigation (2023) Vol. 133, Iss. 11
Open Access | Times Cited: 30
Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature
Davide Marangoni, Roberta Maria Antonello, Marco Coppi, et al.
International Journal of Infectious Diseases (2023) Vol. 133, pp. 53-56
Open Access | Times Cited: 27
SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
Conrad Fischer, Jenson R. Feys
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 80-107
Open Access | Times Cited: 25
Recent Advances on Targeting Proteases for Antiviral Development
Pedro Henrique Oliveira Borges, Sabrina Baptista Ferreira, Floriano Paes Silva
Viruses (2024) Vol. 16, Iss. 3, pp. 366-366
Open Access | Times Cited: 10
DHODH inhibitors: What will it take to get them into the clinic as antivirals?
Anna Luganini, Donatella Boschi, Marco L. Lolli, et al.
Antiviral Research (2025) Vol. 236, pp. 106099-106099
Open Access | Times Cited: 1
The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance
André Schreiber, Franziska Rodner, Nicole Oberberg, et al.
Antiviral Research (2024) Vol. 225, pp. 105840-105840
Open Access | Times Cited: 8
A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy
Shadisadat Esmaeili, Katherine Owens, Jessica Wagoner, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon
Amol D. Gholap, Pankaj R. Khuspe, Sagar R. Pardeshi, et al.
Advanced Therapeutics (2024)
Open Access | Times Cited: 8
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
Irfan Ullah, Fanny Escudié, Ivan Scandale, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109049-109049
Open Access | Times Cited: 6
Computational screening of potential bromodomain-containing protein 2 inhibitors for blocking SARS-CoV-2 infection through pharmacophore modeling, molecular docking and molecular dynamics simulation
Shaohua Xu, Huicheng Yuan, Ling Li, et al.
Arabian Journal of Chemistry (2023) Vol. 17, Iss. 1, pp. 105365-105365
Open Access | Times Cited: 13
Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease
A. Ravi Kumar, Haifa El Kilani, Alina Metzen, et al.
Journal of Medicinal Chemistry (2025)
Open Access
Host-targeted antivirals against SARS-CoV-2 in clinical development - prospect or disappointment?
André Schreiber, Stephan Ludwig
Antiviral Research (2025) Vol. 235, pp. 106101-106101
Open Access
Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens
Tushar Saha, Zia Uddin Masum, Anik Naha Biswas, et al.
Viruses (2025) Vol. 17, Iss. 2, pp. 252-252
Open Access
Influenza H5Nx Viruses are susceptible to MEK1/2 Inhibition by zapnometinib
André Schreiber, Nicole Oberberg, Benjamin Ambrosy, et al.
Emerging Microbes & Infections (2025)
Open Access
Advancing Viral Defense: Unravelling the Potential of Host-Directed Antivirals Against SARS-CoV-2
Zheng Yao Low, Siau Wui Chin, Sharifah Syed Hassan, et al.
Drugs and Drug Candidates (2025) Vol. 4, Iss. 2, pp. 13-13
Open Access
Seven classes of antiviral agents
Aleksandr Ianevski, Shahzaib Ahmad, Kraipit Anunnitipat, et al.
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 12
Open Access | Times Cited: 17
Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents
Shuang Xu, Shadisadat Esmaeili, E. Fabián Cardozo-Ojeda, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 4
Open Access | Times Cited: 3
Gemcitabine combined with baicalein exerts antiviral activity against PEDV by inhibiting the entry and replication phases
Yingge Zheng, Yanfei Zhang, Fangying Xiong, et al.
Animal Diseases (2025) Vol. 5, Iss. 1
Open Access
Broad-spectrum Antiviral Ferruginol Analog Affects the Viral Proteins Translation and Actin Remodeling During Dengue Virus Infection
Vicky C. Roa-Linares, Liliana Betancur‐Galvis, Miguel A. González-Cardenete, et al.
Antiviral Research (2025) Vol. 237, pp. 106139-106139
Closed Access
Papaverine Targets STAT Signaling: A Dual‐Action Therapy Option Against SARS‐CoV‐2
Philipp Reus, Emma Torbica, Tamara Rothenburger, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 4
Open Access
Modulation of in Vitro SARS-CoV-2 Infection by Stephania tetrandra and Its Alkaloid Constituents
Aswad Khadilkar, Zoie L. Bunch, Jessica Wagoner, et al.
Journal of Natural Products (2023) Vol. 86, Iss. 4, pp. 1061-1073
Open Access | Times Cited: 8
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
(2024)
Open Access | Times Cited: 2
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 168-168
Open Access | Times Cited: 2
A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral rebound
Shadisadat Esmaeili, Katherine Owens, Jessica Wagoner, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top